TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04837378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-bed Exercise
Description: In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
Study: NCT04961411

Intervention type: PROCEDURE
Intervention: operation or non-operative treatment
Description: type of operation or if possible non-operative treatment
Study: NCT05060601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gracey micro-curettes
Description: Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gracey curettes
Description: After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
Study: NCT05440552

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Qualitative Fecal immunochemical test + APCS score
Description: Risk stratification using Qualitative Fecal immunochemical test and APCS score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Fecal immunochemical test
Description: Use Quantitative Fecal immunochemical only for risk stratification
Study: NCT05366062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERC1671
Description: ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
Study: NCT06519669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 injection
Description: GT201 injection to treat Advanced lung cancer
Study: NCT05569278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE200486 0.5M Injection
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE200486 0.5M Injection
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE200486 0.5M Injection
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE200486 0.5M Injection
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
Study: NCT04911608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spinal manipulation
Description: High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spinal mobilization
Description: Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
Study: NCT05317741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.
Study: NCT06009848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
Study: NCT05283772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Development of eye tracker for simulation training in nursing
Description: Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks.
Study: NCT06310941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline with hyaluronic acid
Description: Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
Study: NCT06274918

Intervention type: DEVICE
Intervention: Personalized Body-Worn Alcohol Dispenser
Description: This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
Study: NCT06044077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: control pneumococcal polysaccharide vaccine
Description: 23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp
Study: NCT06214234

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Band ligation
Description: Band ligation in variceal bleeding

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Band ligation
Description: Band ligation in variceal bleeding
Study: NCT05415917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Capecitabine
Description: A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle.
Study: NCT04609670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-ALXN2050
Description: A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
Study: NCT06521905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular lithotripsy
Description: The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-pressure ballon
Description: High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
Study: NCT06471348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension
Description: EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride and Epinephrine Injection
Description: Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).
Study: NCT04703075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg and INH 300 mg
Description: Participants will receive Rifapentine 600 mg and INH 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifapentine 900 mg and INH 900 mg
Description: Participants will receive Rifapentine 900 mg and INH 900mg
Study: NCT05226637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT (extra-corporeal shock wave therapy)
Description: The ESWT device (Storz Medical Duolith SD1),

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham : The ESWT device (Storz Medical Duolith SD1),
Description: In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
Study: NCT05291312

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)
Description: IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)
Description: IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
Study: NCT06005064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Superba krill oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: Mixed vegetable oil
Study: NCT04652037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation
Description: Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
Study: NCT06654531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2
Study: NCT06595719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Strain Probiotics
Description: Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replicate for multi-strain probiotics without any active ingredients
Study: NCT06378216

Intervention type: DIAGNOSTIC_TEST
Intervention: neurocognitive evaluations
Description: clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
Study: NCT04781959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
Study: NCT06015152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% Topical Application Lotion [ARAZLO]
Description: \[ARAZLO\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% Topical Application Lotion [ARAZLO]
Description: \[ARAZLO\]
Study: NCT05932667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
Description: Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
Study: NCT04922567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg po on day 1-10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m² iv on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m² iv on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m² iv on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m² iv on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg po on day1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg po on day1-5
Study: NCT06296329

Intervention type: OTHER
Intervention: Rubber Hand Illusion
Description: The traditional behavioural illusion of the Rubber Hand will be applied

Intervention type: OTHER
Intervention: Rubber Hand Illusion
Description: The traditional behavioural illusion of the Rubber Hand will be applied
Study: NCT06165289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
Study: NCT05959148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monochromatic infrared energy
Description: The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
Study: NCT05885399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
Study: NCT05372172

Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study

Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study

Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study
Study: NCT06322654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotically Assisted Locomotion
Description: * Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotically Assisted Verticalization
Description: * Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy
Study: NCT06442878

Intervention type: OTHER
Group type: OTHER
Intervention: Belly Dance Program
Description: All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
Study: NCT05907057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500mg Oral Tablet
Description: Provided as tablets, taken orally as two 250mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.